---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046163"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:02:03.003035+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports Q4/FY24 net loss $22.8M/$80.6M; ACR-368 endometrial cancer cORR 35% in BM+ patients

## Summary
- Cash $184.6M as of Dec 31, 2024; runway extended into 2027.
- ACR-368 in BM+ endometrial cancer: 35% cORR, 80% DCR; in relapsed patients cORR 50% with mDOR >10 months.
- Phase 1 ACR-2316 cleared doses 1-2; dose 3 shows tumor shrinkage; target engagement confirmed.
- Endometrial cancer prioritized; ovarian and bladder deprioritized due to competition/low BM+ rate.
- R&D expenses $64.0M for FY24 vs $46.0M in FY23, driven by ACR-368 and ACR-2316 clinical trials.

## SEC filing metadata
- accession: 0000950170-25-046163
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017025046163/0000950170-25-046163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017025046163/acrv-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046163
- JSON: https://secwatch.observer/filing/0000950170-25-046163.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.